Edwards Lifesciences Corporation $EW Stock Holdings Boosted by BNP Paribas Financial Markets

Key Points

• BNP Paribas Financial Markets increased its stake in Edwards Lifesciences Corporation by 37%, acquiring an additional 525,822 shares, bringing its total holdings to 1,946,818 shares valued at approximately $141 million.
• Edwards Lifesciences reported a quarterly earnings per share (EPS) of $0.67, exceeding analyst expectations of $0.62, and had revenue of $1.53 billion during the quarter, a year-over-year increase of 11.9%.
• Institutional investors own about 79.46% of Edwards Lifesciences, reflecting strong interest in the company's stock among major financial firms.

BNP Paribas Financial Markets lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 37.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,946,818 shares of the medical research company's stock after buying an additional 525,822 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.33% of Edwards Lifesciences worth $141,105,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. B. Metzler seel. Sohn & Co. AG grew its holdings in shares of Edwards Lifesciences by 3.9% during the first quarter. B. Metzler seel. Sohn & Co. AG now owns 66,107 shares of the medical research company's stock worth $4,791,000 after buying an additional 2,461 shares in the last quarter. Ieq Capital LLC grew its holdings in shares of Edwards Lifesciences by 50.2% during the first quarter. Ieq Capital LLC now owns 69,312 shares of the medical research company's stock worth $5,024,000 after buying an additional 23,151 shares in the last quarter. Epoch Investment Partners Inc. grew its holdings in Edwards Lifesciences by 15.4% in the first quarter. Epoch Investment Partners Inc. now owns 350,973 shares of the medical research company's stock valued at $25,439,000 after purchasing an additional 46,772 shares during the period. Caisse DE Depot ET Placement DU Quebec purchased a new stake in Edwards Lifesciences in the first quarter valued at approximately $619,000. Finally, Kayne Anderson Rudnick Investment Management LLC grew its holdings in Edwards Lifesciences by 186.9% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 2,941 shares of the medical research company's stock valued at $213,000 after purchasing an additional 1,916 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

EW has been the subject of a number of recent analyst reports. Truist Financial boosted their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a report on Friday, July 25th. Wells Fargo & Company boosted their price objective on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Stifel Nicolaus boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research note on Friday, July 25th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus price target of $85.90.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of the company's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president directly owned 50,356 shares of the company's stock, valued at $3,897,554.40. This represents a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,584 shares of company stock valued at $1,897,762 over the last ninety days. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Stock Up 0.3%

EW traded up $0.25 during trading on Friday, hitting $81.48. The company had a trading volume of 2,743,784 shares, compared to its average volume of 3,802,425. The company has a market cap of $47.84 billion, a PE ratio of 11.72, a P/E/G ratio of 3.92 and a beta of 1.07. The business has a 50-day moving average of $78.31 and a 200-day moving average of $75.01. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm's quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.